New hope for treatment-resistant ovarian cancer

Credit: Getty Images/Marcin Klapczynski

By Olivia Bowthorpe

Scientists have discovered a potential breakthrough in treating high-grade serous carcinoma, the most common type of ovarian cancer.

The new research, published in Cancer Research Communications, has found that combining an experimental drug called SM08502 (cirtuvivint) with the PARP inhibitor olaparib can overcome resistance and “significantly” reduce tumour progression and extend survival.